Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment in Colombia for Melanoma Patients with Lymph Node Involvement After Complete Resection

INTRODUCTION: The KEYNOTE-054 trial found that adjuvant treatment with pembrolizumab improved recurrence-free survival versus placebo in completely resected high-risk stage III melanoma patients. We assessed the cost-effectiveness of adjuvant pembrolizumab in Colombia compared with watchful waiting,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez-Vinueza, Cesar, Urrego-Reyes, Juan, Gutierrez, Fredy R. S., Wurcel, Victoria, Zhang, Shujing, Jiang, Shan, Jiang, Ruixuan, Zambrano Harvey, Angela, Dhankhar, Praveen, Sawhney, Baanie, Baluni, Gargi, Jain, Shrishti, Bhadra, Debosmita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219874/
https://www.ncbi.nlm.nih.gov/pubmed/37129772
http://dx.doi.org/10.1007/s12325-023-02484-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219874/
https://www.ncbi.nlm.nih.gov/pubmed/37129772
http://dx.doi.org/10.1007/s12325-023-02484-3

Ejemplares similares